In a turbulent market environment, Cytokinetics , Incorporated (NASDAQ:CYTK) stock has reached its 52-week low, trading at $41.69, with a sharp 14% decline just last week. According to InvestingPro ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), currently valued at approximately $5 billion in market capitalization, has announced the appointment of Robert E. Landry to its Board ...

Cytokinetics (CYTK) announced the appointment of Robert Landry to its Board of Directors. Mr. Landry brings over three decades of financial and ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

在动荡的市场环境下，Cytokinetics, Incorporated (CYTK)股价触及52周新低，报41.69美元，仅上周就下跌了14%。根据 InvestingPro 分析，该股票在当前价位显示估值过高。这一价格水平反映出这家专注于肌肉生物学和相关疗法的生物制药公司面临重大下滑。过去一年，Cytokinetics股价下跌了47.24%，这一大幅下跌引起了投资者和市场分析师的关注。尽管面临 ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

南旧金山 - 市值约50亿美元的Cytokinetics, Incorporated (NASDAQ: CYTK )宣布任命Robert E.